Skip to main content
SpringerLink
Log in

Adjuvant Chemotherapy in Premenopausal Patients: A More Complicated Form of Oophorectomy?

  • Chapter
Endocrine Therapy of Breast Cancer

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

Surgical oophorectomy and ovarian radiation have each been shown to increase disease-free survival and overall survival (DFS and OS) in some trials. Retrospective analyses of some of the other trials which tested the effect of chemotherapy have shown amenorrhea to be associated with increased DFS and OS. The type of alkylating agent used in these trials (cyclophosphamide), the dose of drug and the compliance with prescribed treatment might influence the degree of suppression of ovarian function.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Henderson IC, Canellos GP: Cancer of the breast: the past decade. N Engl J Med 1980 (302):17–30

    Article  PubMed  CAS  Google Scholar 

  2. Beatson GT: On the treatment of inoperable cases of carcinoma of the mammae: suggestions for a new method of treatment with illustrative cases. Lancet 1986 (11):104–107

    Google Scholar 

  3. Baum M: Breast cancer — lessons from the past. Clinics in Oncology 1982 (3):649–660

    Google Scholar 

  4. Cole MP: Prophylactic compared with therapeutic x-ray artificial menopause. 2nd Tenovus Workshop of Breast Cancer 1970, pp 2–11

    Google Scholar 

  5. Nissen-Meyer R, Kjellgren K, Malmio K, Mansson B, Norin T: Surgical adjuvant chemotherapy. Results with one short course of cyclophosphamide after mastectomy for breast cancer. Cancer 1978 (41):2088–2098

    Article  PubMed  CAS  Google Scholar 

  6. Fisher B, Slack NH, Katrych D, Wolmark N: Ten years of follow-results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975 (140):528–534

    PubMed  CAS  Google Scholar 

  7. Henderson IC: Adjuvant systemic therapy of early breast cancer. In: Harris JR, Hellman S, Henderson IC and Kinne DW (eds) Breast Disease. Lippincott, Philadelphia 1987, pp 324–353

    Google Scholar 

  8. Nissen-Meyer R: Adjuvant cytostatic and endocrine therapy: increased cure rate or delayed manifest disease. In: Bulbrook RD, Taylor DJ (eds) Commentaries on Research in Breast Disease. Vol 1. Alan R Liss, New York 1979 pp 95–109

    Google Scholar 

  9. Ravdin RG, Lewison EF, Slack NH et al.: Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg Gynecol Obstet 1970 (31):1055–1064

    Google Scholar 

  10. Nevinny HB, Nevinny D, Rosoff CB et al.:Prophylactic oophorectomy in breast cancer therapy: a preliminary report. Am J Surg 1969 (117):531–536

    Article  Google Scholar 

  11. Bryant AJ, Weir JA: Prophylactic oophorectomy in operable instances of carcinoma of the breast. Surg Gynecol Obstet 1981 (153):660–664

    PubMed  CAS  Google Scholar 

  12. Meakin JW, Allt WEG, Beale FA et al.: Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res Treat 1983 (3, suppl):45–48

    Article  Google Scholar 

  13. Meakin JW, Allt WEC, Beale FA et al.: Ovarian irradiation and prednisone therapy following surgery and radiotherapy for carcinoma of the breast. Can Med Assoc J 1979 (120):1221–1228

    PubMed  CAS  Google Scholar 

  14. Koyama H, Wada T, Nishzawa Y, Takeshi I, Aoki Y, Terasawa T, Kosaki G, Yamamoto T, Wada A: Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977 (39):1403–1409

    Article  PubMed  CAS  Google Scholar 

  15. Rose DP and Davis TE: Effects of adjuvant chemo-hormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res 1980 (40):4043–4047

    PubMed  CAS  Google Scholar 

  16. Fisher B, Sherman B, Rockette H, Redmond C, Margolese R and Fisher ER: 1-Phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of DFS with depression of ovarian function. Cancer 1979 (44):847–857

    Article  PubMed  CAS  Google Scholar 

  17. Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Zambetti M, Veronesi U: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 1985 (5):95–115

    Article  PubMed  CAS  Google Scholar 

  18. Padmanabhan N, Howell A, Rubens RD: Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet 1986 (II):411–414

    Article  Google Scholar 

  19. Tormey DC: Adjuvant systemic therapy in postoperative node+ patients with breast carcinoma: the CALGB trial and the ECOG premenopausal trial. In: Senn HJ (ed) Recent Results in Cancer Research. Adjuvant Chemotherapy of Breast Cancer. Springer Verlag, Heidelberg-Berlin 1984 pp 155–165

    Google Scholar 

  20. Brickner H, Mouridsen HT, Rank F, Rose C and Andersen KW: Evidence of a castration-mediated effect of adjuvant chemotherapy (CT) in a randomized trial of cyclophosphamide monotherapy versus CMF in premenopausal stage II breast cancer. Proc Am Soc Clin Oncol 1985 (4):56

    Google Scholar 

  21. Ludwig Breast Cancer Study Group: A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 1985 (45):4454–4459

    Google Scholar 

  22. Valagussa P, Bonadonna G: Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet 1986 (II):1035–1036

    Article  Google Scholar 

  23. Palshof T, Carstensen B, Mouridsen HT, Dombernowsky P: Adjuvant endocrine therapy in pre- and postmenopausal women with operable breast cancer. Review on Endocrine-Related Cancer 1985 (17):43–50

    Google Scholar 

  24. Ribiero G, Swindell R: The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma — 7-year results. Eur J Cancer Clin Oncol 1985 (21):897–900

    Article  Google Scholar 

  25. Baum M: Nolvadex Adjuvant Trial Organisation — Controlled trial of tamoxifen as single agent in management of early breast cancer: analysis at 6 years. Lancet 1985 (1):836–839

    Google Scholar 

  26. Kaufmann M, Jonat W, Caffier H et al.: Adjuvant systemic risk adapted cytotoxic +/− tamoxifen therapy in women with node-positive breast cancer. Proceedings of the 5th International Conference on the Adjuvant Therapy of Cancer. Arizona Cancer Center, Tucson 1987 pp 57

    Google Scholar 

  27. Jordan VC: Towards an optimal strategy for the adjuvant therapy of breast cancer. In: Cavalli F (ed) Endocrine Treatment of Breast Cancer I: Concepts and Strategies. European School of Oncology Monographs, Springer Verlag, Heidelberg 1986 pp 109–116

    Google Scholar 

  28. Brunner KW, Sonntag RW, Alberto P et al.: Combined chemo- and hormonal therapy in advanced breast cancer. Cancer 1977 (39):2923–2933

    Article  PubMed  CAS  Google Scholar 

  29. Hug V, Hortobagyi GN, Drewinko B et al.:Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro. J Clin Oncol 1985 (3):1672–1677

    PubMed  CAS  Google Scholar 

  30. Marshall JS, Hubay CA, Pearson OH et al.: Adjuvant tamoxifen therapy in stage II breast cancer. Breast Cancer Res Treat 1985 (6):167

    Google Scholar 

  31. Fisher B, Redmond C, Brown A et al.: Adjuvant chemotherapy with and without tamoxifen: five-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986 (4):459–471

    PubMed  CAS  Google Scholar 

  32. Everson LK, Ingle NJ, Wieand HS et al.: Randomized trial of adjuvant therapy with cyclophosphamide (C), 5-fluorouracil (F), prednisone (p) with or without tamoxifen (T) following mastectomy in premenopausal women with node-positive breast cancer. Proc Am Soc Clin Oncol 1986 (5):70

    Google Scholar 

  33. Ludwig Breast Cancer Study Group: Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J Clin Oncol 1985 (3):1059–1067

    Google Scholar 

  34. Osborne CK, Rivkin SE, McDivitt RW et al.: Adjuvant therapy of breast cancer: Southwest Oncology Group studies. NCI Monographs 1986 (1):71–74

    PubMed  Google Scholar 

  35. Goldhirsch A, Gelber RD, Mouridsen H: Endocrine aspects in adjuvant therapy for early breast cancer. In: Cavalli F (ed) Endocrine Therapy of Breast Cancer I: Concepts and Strategies. European School of Oncology Monographs, Springer Verlag, Heidelberg 1986 pp 91–107

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ludwig Institute for Cancer Research (Bern Branch), Inselspital, Bern, Switzerland

    A. Goldhirsch

  2. Harvard School of Public Health and Dana-Farber Cancer Institute, Boston, MA, USA

    R. D. Gelber

  3. Finsen Institute, Copenhagen, Denmark

    H. Mouridsen

Authors
  1. A. Goldhirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. D. Gelber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Mouridsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Oncology, Ospedale San Giovanni, 6500, Bellinzona, Switzerland

    Franco Cavalli

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Goldhirsch, A., Gelber, R.D., Mouridsen, H. (1987). Adjuvant Chemotherapy in Premenopausal Patients: A More Complicated Form of Oophorectomy?. In: Cavalli, F. (eds) Endocrine Therapy of Breast Cancer. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72983-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72983-6_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-72985-0

  • Online ISBN: 978-3-642-72983-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation